Karyopharm Therapeutics Inc. (KPTI) Trading Up 27.1%
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares were up 27.1% during trading on Tuesday . The company traded as high as $9.45 and last traded at $9.05, with a volume of 1,809,335 shares changing hands. The stock had previously closed at $7.12.
A number of research analysts recently commented on KPTI shares. Zacks Investment Research raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, July 21st. Wedbush reissued an “outperform” rating and issued a $14.00 price objective on shares of Karyopharm Therapeutics in a research report on Thursday, August 4th. Jefferies Group lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating and set a $14.00 price objective on the stock. in a research report on Wednesday, June 1st. Leerink Swann reissued a “buy” rating on shares of Karyopharm Therapeutics in a research report on Monday, June 27th. Finally, Raymond James Financial Inc. assumed coverage on shares of Karyopharm Therapeutics in a research report on Friday, May 27th. They issued an “outperform” rating and a $13.00 price objective on the stock. Two analysts have rated the stock with a sell rating and ten have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $17.08.
The company’s market cap is $350.17 million. The company has a 50-day moving average price of $7.22 and a 200 day moving average price of $7.92.
Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, August 4th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by $0.08. On average, equities research analysts anticipate that Karyopharm Therapeutics Inc. will post ($3.26) EPS for the current year.
In related news, major shareholder Ltd Chione sold 18,824 shares of the business’s stock in a transaction dated Thursday, June 23rd. The shares were sold at an average price of $8.03, for a total transaction of $151,156.72. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.